A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
7 Hills Pharma, LLC
Istituto Oncologico Veneto IRCCS
Essen Biotech
Essen Biotech
Conjupro Biotherapeutics, Inc.
Second Life Therapeutics
University Health Network, Toronto
UNC Lineberger Comprehensive Cancer Center
MacroGenics
Washington University School of Medicine
Milton S. Hershey Medical Center
Columbia University
Tvardi Therapeutics, Incorporated
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NantBioScience, Inc.
Xencor, Inc.
Pfizer
Pfizer
Celldex Therapeutics
Massachusetts General Hospital
Klus Pharma Inc.
Xencor, Inc.
Bristol-Myers Squibb
Quadriga Biosciences, Inc.
Xencor, Inc.
Pfizer
Hospices Civils de Lyon
National Institutes of Health Clinical Center (CC)
MultiVir, Inc.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Stanford University
Santa Maria Biotherapeutics
OrienGene Biotechnology Ltd.
University of Pittsburgh
Northwest Biotherapeutics
University of Chicago
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Mannkind Corporation
NS Pharma, Inc.
FeRx